Physician profile
Adriana Gomez
NPI 1588079388
$4,587.24
in general payments reported to CMS, 2019-2025
24 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.88 · 2020: $285 · 2021: $772 · 2022: $654 · 2023: $1,032 · 2024: $759 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,056.45 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $708.79 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $382.22 | 2023-2025 | Repatha, Repatha, Otezla |
| Exact Sciences Corporation | $285.84 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $213.63 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $203.55 | 2020-2022 | |
| Glaxosmithkline, LLC. | $115.27 | 2020-2024 | Shingrix, Arexvy |
| Abbvie INC. | $67.79 | 2024 | |
| Inspire Medical Systems, INC. | $67.37 | 2023-2025 | Inspire |
| Currax Pharmaceuticals LLC | $60.61 | 2024-2025 | Onzetra Xsail, Contrave |
| Sanofi-Aventis U.S. LLC | $56.32 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.36 | 2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $41.55 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $36.96 | 2024-2025 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $35.05 | 2024-2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $34.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.22 | 2024 | Hyqvia |
| Ethicon US, LLC | $24.85 | 2020 | |
| Janssen Pharmaceuticals, INC | $23.81 | 2021 | |
| Medtronic, INC. | $22.44 | 2022 | |
| Genentech USA, INC. | $18.18 | 2021 | |
| Eisai INC. | $17.39 | 2025 | |
| Organon LLC | $17.20 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.05 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adriana Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.